Silexion Therapeutics Gains German Approval for Pivotal Phase 2/3 Pancreatic Cancer Trial
SLXN sits 17% above its 52-week low of $2.31 on light trading volume (0.1× avg).
Summary
Silexion Therapeutics received unconditional approval from Germany's BfArM to initiate its Phase 2/3 clinical trial for SIL204 in locally advanced pancreatic cancer. This follows earlier approval in Israel, positioning the company to begin the trial across both countries, with first patient dosing expected in the coming weeks. This positive clinical development is a critical step for the micro-cap biotech, especially given its recent financial challenges, including a 1-for-10 reverse stock split effective May 29, 2026, and a Q1 going concern warning. Advancing a lead candidate into a pivotal late-stage trial for a highly lethal cancer like pancreatic cancer is a major de-risking event and could significantly impact the company's valuation. The company expects first patient dosing in the coming weeks.
At the time of this announcement, SLXN was trading at $2.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.9M. The 52-week trading range was $2.31 to $223.60. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.